Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia

Summary

This is a phase 2a, multicenter, randomized, double-blinded, placebo controlled, dose escalation study in adult subjects with COVID-19 pneumonia. The primary objective of this study is to evaluate the overall safety of F-652 in COVID subjects in order to identify safe dose(s) for future studies with adequate patient numbers to demonstrate clinical efficacy.

Timeline

Start

2022-04-08

Primary completion

2022-04-08

Completion

2023-04-08

Drugs

Indications